Phase 2 cohort-2 trial in progress: Vabametkib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation.
Authors: Dae Ho Lee, Hye Ryun Kim, Hanlim Moon, Inyoung Kim, Nirmal Rajasekaran, Sunyhe Im, Na Young Kim, Jun Young Choi, Youngkee Shin, Se-Hoon Lee